A practical reference on BPC-157: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-15. Anything still debated is marked as such rather than presented as settled.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Founded in 1957 as a sub-organization of the Organization for Economic Cooperation and Development (OECD), the Nuclear Energy Agency (NEA) pools the scientific and financial resources of participating countries' nuclear research programs. It operates various databases and also manages the International Reporting System for Operating Experience (IRS or IAEA/NEA Incident Reporting System) of the International Atomic Energy Agency (IAEA). The IAEA records and investigates radiation accidents that have occurred worldwide in connection with nuclear medical procedures and the disposal of related materials. The International Nuclear and Radiological Event Scale (INES) is a scale for safety-related events, in particular nuclear incidents and accidents in nuclear facilities. It was developed by an international group of experts and officially adopted in 1990 by the International Atomic Energy Agency (IAEA) and the Nuclear Energy Agency of the Organization for Economic Cooperation and Development (OECD). The purpose of the scale is to inform the public quickly about the safety significance of an event by means of a comprehensible classification of events. At the end of its useful life, the proper disposal of the remaining high activity is of paramount importance.
Pharmacometabolomics, also known as pharmacometabonomics, is a field which stems from metabolomics, the quantification and analysis of metabolites produced by the body. It refers to the direct measurement of metabolites in an individual's bodily fluids, in order to predict or evaluate the metabolism of pharmaceutical compounds, and to better understand the pharmacokinetic profile of a drug. Alternatively, pharmacometabolomics can be applied to measure metabolite levels following the administration of a pharmaceutical compound, in order to monitor the effects of the compound on certain metabolic pathways(pharmacodynamics). This provides detailed mapping of drug effects on metabolism and the pathways that are implicated in mechanism of variation of response to treatment. In addition, the metabolic profile of an individual at baseline (metabotype) provides information about how individuals respond to treatment and highlights heterogeneity within a disease state. All three approaches require the quantification of metabolites found in bodily fluids and tissue, such as blood or urine, and can be used in the assessment of pharmaceutical treatment options for numerous disease states.
== Bibliography == Oberg, Erik; Jones, Franklin D.; Horton, Holbrook L.; Ryffel, Henry H. (1996), Green, Robert E.; McCauley, Christopher J. (eds.), Machinery's Handbook (25th ed.), New York: Industrial Press, ISBN 978-0-8311-2575-2, OCLC 473691581.
Sources: en.wikipedia.org
(WINNER) The contestant won the whole competition. (WIN) The contestant won the Haunted Heat (HIGH) The contestant had one of the best dishes in the Haunted Heat. (IN) The contestant performed well enough to move on to the next week. (RISK) The contestant had one of the bottom dishes in the Haunted Heat and competed in the Bake for Your Life challenge, but was not eliminated. (LOW) The contestant had one of the bottom dishes in the episode's only challenge but was not eliminated. (OUT) The contestant was eliminated for worst dish. (WDR) The contestant withdrew from the competition.
==== Epidemics of occupational silicosis ==== In the United States, a 1930 epidemic of silicosis due to the construction of the Hawks Nest Tunnel near Gauley Bridge, West Virginia, caused the death of at least 400 workers. Other accounts place the mortality figure at well over 1000 workers, primarily African American transient workers from the southern United States. The goldmining establishment of Delamar Ghost Town, Nevada, was afflicted by a dry-mining process that produced a silicosis-causing dust, because the gold was embedded in quartzite. The town was nicknamed "the widowmaker" after hundreds of silicosis-related deaths. A nozzle spraying a mist of water was added to the drill, which turning the dust raised by drilling into mud, but this inhibited mining work. Silicosis has been identified as one of many long-term health outcomes for first responders from the terrorist attacks of September 11, 2001, after having been exposed to dust containing high concentrations of respirable crystalline silica, as well as other metals and toxins.
In 2020, Schmitt was among 17 Republican attorneys general who joined Texas attorney general Ken Paxton in suing Georgia, Michigan, Wisconsin, and Pennsylvania to invalidate their electoral votes in the 2020 United States presidential election. The suit claimed the four states' presidential vote tallies were unconstitutional; no evidence supported these claims and the arguments had already been rejected in other state and federal courts. On December 11, 2020, the Supreme Court rejected the suit in an unsigned opinion.
Sources: en.wikipedia.org
The aerosol or spallation frangible powder produced by impact and combustion of depleted uranium munitions (or armour) can potentially contaminate wide areas around the impact sites, leading to possible inhalation by human beings. The actual level of acute and chronic toxicity of DU is also controversial. Several studies using cultured cells and laboratory rodents suggest the possibility of leukemogenic, genetic, reproductive, and neurological effects from chronic exposure. A 2005 epidemiology review concluded "In aggregate the human epidemiological evidence is consistent with increased risk of birth defects in offspring of persons exposed to DU." A 2021 study concluded that DU from exploding munitions did not lead to Gulf War illness in American veterans deployed in the Gulf War. A 2011 study found elevated levels of uranium in soil and hair samples from Fallujah, Iraq, but it was from slightly enriched uranium instead of DU.
N-terminal ATPase domain – binds ATP (Adenosine triphosphate) and hydrolyzes it to ADP (Adenosine diphosphate). The NBD (nucleotide binding domain) consists of two lobes with a deep cleft between them, at the bottom of which nucleotide (ATP and ADP) binds. The exchange of ATP and ADP leads to conformational changes in the other two domains. Substrate binding domain – is composed of a 15 kDa β sheet subdomain and a 10 kDa helical subdomain. The β sheet subdomain consists of stranded β sheets with upward protruding loops, which enclose the peptide backbone of the substrate. SBD contains a groove with an affinity for neutral, hydrophobic amino acid residues. The groove is long enough to interact with peptides up to seven residues in length. C-terminal domain – rich in alpha helical structure acts as a 'lid' for the substrate binding domain. The helical subdomain consists of five helices, with two helices packed against two sides of the β sheet subdomain, stabilizing the inner structure. In addition, one of the helix forms a salt bridge and several hydrogen bonds to the outer Loops, thereby closing the substrate-binding pocket like a lid. Three helices in this domain form another hydrophobic core which may be stabilization of the "lid". When an Hsp70 protein is ATP bound, the lid is open and peptides bind and release relatively rapidly. When Hsp70 proteins are ADP bound, the lid is closed, and peptides are tightly bound to the substrate binding domain.
It also has the largest Brazilian community in the UK; one of the largest Indian communities; a significant Afro-Caribbean community; and more recent Romanian, Polish and Somali communities. The 2021 census showed that 1.3% of adults in Brent identified as transgender, derived from the Census question, "Is the gender you identify with the same as your sex registered at birth?". This gave Brent the second highest proportion of transgender adults after the Borough of Newham (at 1.5%). The overall proportion in England and Wales was 0.5% with Brighton, an area well known for its LGBT communities, 1%. However, Prof Michael Biggs of Oxford University showed there was a correlation between the proportion of transgender people in these areas and the proportion for whom English was not their first language (34% in Brent and 35% in Newham, compared to 9% nationally), suggesting the question was not fully understood by some. Prof Biggs described the figures as "irredeemably flawed". In September 2024, Mary Gregory, a deputy director at the ONS said some people may have misunderstood the question, saying there was "potential bias" in how the question was answered "by those who responded that they had lower levels of English proficiency, some of whom may have mistakenly given an answer suggesting they were trans". As a result, the ONS downgraded the data from "accredited official statistics" to "official statistics in development" to reflect the possible flaws.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.